To compare survival outcome between chemoradiation therapy (CRT) and radical cystectomy (RC) for muscleinvasive bladder cancer (MIBC).
Introduction
Radical cystectomy (RC) is the standard of care for muscleinvasive bladder cancer (MIBC). However, due to the relatively high morbidity and quality-of-life concerns with RC, there is growing interest in bladder preservation treatment strategies [1] . The combined use of chemotherapy with radiotherapy, termed chemoradiation therapy (CRT), is the most widely used bladder preservation technique [1] . Additionally, CRT may be combined with an aggressive debulking transurethral bladder tumour resection (TURBT) and is referred to as 'tri-modality therapy' (TMT) [2] . CRT series have shown modest results for overall (OS) and diseasespecific survival (DSS) [3] . Efstathiou et al. [3] reported the Massachusetts General Hospital experience and demonstrated a 72% complete response (CR) rate, with a 10-year DSS and OS of 59% and 35%, respectively. Although not directly comparable, these CRT data do not appear inferior to those for RC with a 10-year DSS and OS of 66.8% and 44.3%, respectively [4] . With respect to morbidity, phase II clinical trials of CRT have 6-11% of radiotherapy-related grade 3-4 toxicities (mainly contracted bladder and/or haematuria) and 19-35% of chemotherapy-related grade 3-4 toxicities (mainly haematological, metabolic, and genitourinary) [5] . Postoperative complications are common after RC, and are as high as 41% (38% minor, 7.4% major) [6] . Therefore, the potential for equivalent survival, along with decreased morbidity from bladder preservation have fuelled interest in CRT.
Currently, there are few studies comparing CRT to RC, most probably due to the limited experience at most institutions with CRT and the prevalent use of RC for MIBC. In clinical practice, the use of CRT is generally limited to the elderly and/or infirm, who cannot tolerate RC. Thus, patient selection bias is a major confounder when comparing outcomes of both treatments. However, there is a critical need for data to determine whether survival rates are equivalent and whether CRT represents a viable option for a wider patient population. We therefore sought to perform a comparative analysis of OS after CRT vs RC in patients with cT2-4, N0, M0 MIBC from the National Cancer Database (NCDB) using a propensity score-adjusted model to control for patient selection bias.
A recent study conducted in the NCDB comparing TMT to RC using inverse probability of treatment weighting, to adjust for selection bias, found that there was no difference in median survival between groups but when adjusted for time, RC patients had a survival benefit after 2 years [7] . Given that there are several limitations to national registry studies, specifically: variations in treatment definitions, population selection, and variability in statistical methods used to analyse data, alternate independently conducted studies within the same registry can provide additional significant findings. In the NCDB, there is no strict definition for TMT or CRT, or the population who meet each of these criteria, therefore, the associated survival outcomes may differ significantly depending on these definitions. Furthermore, alternative statistical methods, such as propensity scoring, may reveal relevant findings. We therefore conducted an independent comparative analysis of the NCDB, using propensity scoring to control for selection bias, along with an alternate clinically appropriate definition for CRT, to determine whether a survival difference exists between CRT and RC in patients with MIBC.
Patients and Methods

Data Source and Patient Population
The NCDB, is a nationwide oncology registry in the USA that collects information on 70% of all new invasive cancers annually diagnosed in the USA [8] . Data from the NCDB can be used to conduct clinical studies related to cancer care [8] . Retrospective data were extracted from 2004 to 2013 for patients with urothelial carcinoma of the bladder. Patients with cT2-T4, N0, M0 bladder cancer who underwent either RC or CRT as their first treatment after diagnosis were included. Patients were excluded if they had non-MIBC: cTis-T1, or any metastatic (cM+) disease, a treatment delay of ≥90 days from time of diagnosis, diagnosed at the time of autopsy, or presence of other primary malignancies.
Treatment Definitions
To determine primary treatment method, therapy had to be initiated within 90 days of diagnosis. To define a treatment population who received only RC or CRT as primary therapy with curative intent, we excluded patients who received multimodal combined chemotherapy, RC, and radiation therapy within 90 days of diagnosis. We also excluded patients who had monotherapy with chemotherapy or radiotherapy within 90 days of diagnosis, as this is not the standard of care for curative treatment of MIBC. Surgery was coded as radical/ total cystectomy with urinary diversion, or pelvic/total exenteration, as per the NCDB definitions and these patients were categorised as receiving RC as their primary treatment method. We included patients with and without perioperative chemotherapy in this RC group. To define patients who had primary CRT, we applied our inclusion and exclusion criteria to those who did not have RC as their primary treatment, but instead had documented radiation therapy as their first course of treatment within 90 days of diagnosis. We then considered these patients as having primary CRT if they received chemotherapy within 90 days of radiation. In addition, we excluded patients who may have received CRT for palliative purposes by excluding those with a radiation dose of <40 Gy and therefore only included those categorised as undergoing CRT with curative intent (defined as a radiation dose of ≥40 Gy) [2] .
Statistical Analysis
Variables for analysis, including demographic variables: age, race, gender, income, and clinical variables: stage, grade, histological sub-type, and Charlson-Deyo Comorbidity score, were interrogated using numeric and graphical exploratory data analysis (EDA) techniques [9] . Due to the small proportion of patients in the NCDB with a high number of comorbidities, the Charlson-Deyo Comorbidity score is truncated to 0, 1 and 2. Based on the findings from the EDA of continuous variables, treatment groups were compared using parametric (e.g., t-tests) or non-parametric methods (e.g., Wilcoxon tests). Means with standard deviations (SDs) or medians with interquartile ranges are reported where appropriate. Categorical variables were summarised and presented using contingency tables and chi-squared tests. Given the findings from the EDA and knowledge from clinical practice patterns that suggest that patients selected for primary CRT are typically older and have more comorbidity,
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© 2018 The Authors BJU International © 2018 BJU International we performed propensity score analyses to identify patients who had similar probabilities of undergoing either CRT or RC. Multivariate logistic regression methods were used to model the probability of receiving CRT using age, gender, race, income, Charlson-Deyo Comorbidity score, and clinical T stage as predictors. Patients who received CRT were matched one-to-one with those who had RC based on each individual's predicted probability using an established matching algorithm [10] .
Kaplan-Meier methods with log-rank tests and Cox regression methods were used to compare survival and hazards of death. Proportional hazards were checked using a variety of EDA methods including log-log plots; smoothed estimated hazard functions; Lin, Wei and Ying's cumulative martingale residual analysis; as well as modelling interactions with time in an extended Cox framework [11] . Hazard ratios (HRs) for OS were modelled using multivariate Cox regression methods adjusting for age, gender, race, ethnicity, income, treatment type (RC vs CRT), Charlson-Deyo Comorbidity score, stage, grade, and histology. Two-tailed P values of < 0.05 were considered statistically significant for all analyses. All statistical analysis was performed using Statistical Analysis System (SAS) software, version 9.4. (SAS Institute Inc., Cary, NC, USA).
Results
We identified a total of 35 374 and 5 623 patients who underwent RC and CRT, respectively. Following exclusions, there were 6 606 primary RC and 1 773 primary CRT patients treated for cT2-T4, N0, M0 bladder cancer. The median follow-up was 45.3 months. The median age for all patients was 69 years and patients treated with CRT were older than those who underwent RC (77 vs 67 years, P < 0.001). Most patients in both groups were Caucasian (91% RC and 89% CRT) and male (65% RC and 70% CRT); however, there were more females who had RC than CRT (35% vs 30%, P < 0.001). There was no significant difference for median income quartiles between patients who had CRT compared to RC (Table 1 ). For comorbidity, RC patients were generally healthier with a higher proportion having a Charlson-Deyo Comorbidity score of 0 compared to those treated with CRT (70% vs 66%, P < 0.01). Significantly more patients treated with CRT had multiple comorbidities (Charlson-Deyo Comorbidity score of 2) compared to RC patients (11% vs 7%, P < 0.001) ( Table 1) .
Most patients were cT2 (79% RC and 77% CRT) and had high-grade disease (85% RC and 83% CRT). Urothelial carcinoma was the most common histological type (65% RC and 60% CRT); however, urothelial variant sub-types were more common in the CRT group (29% vs 24% RC, P < 0.001). Propensity scores matching yielded 1 683 patients per treatment group. Patients were similarly matched for age, race, gender, income, Charlson-Deyo Comorbidity score, clinical T stage, grade, and histological type. The median age for the matched cohort was 76 years (76 years for RC and 77 years for CRT) and most patients had a Charlson-Deyo Comorbidity score of 0 (66% RC and 66% CRT) ( Table 2 ).
On Kaplan-Meier survival analysis of the matched cohort, adjusted for age, Charlson-Deyo Comorbidity score, stage, grade and histological type, the median 5-year OS was worse for patients undergoing CRT than for those undergoing RC (30% vs 38%, P < 0.004) (Fig. 1) . There was a significant interaction between treatment type and time such that initially after treatment, OS was lower with RC compared to CRT until~16 months, at which point there was a significant monthly increase in the likelihood of death after CRT compared to RC that persisted throughout the follow-up period (Fig. 1) . Multivariable extended Cox regression modelling, adjusting for confounding variables (age, comorbidity, stage, histology, grade) to predict the hazard of mortality for patients undergoing RC or CRT, showed that there was a significant decreased likelihood of mortality within the first year for patients undergoing CRT (HR 0.84, 95% CI 0.74-0.96; P = 0.01). However, in years 2 and 3, and onwards, there was a statistically significant persistent increased likelihood of mortality after CRT compared to RC (year 2: HR 1.4, 95% CI 1.2-1.6, P < 0.001; and year 3 onwards: HR 1.5, 95% CI 1.2-1.8, P < 0.001). In addition, age (HR 1.4, 95% CI 1.3-1.6; P < 0.001), Charlson-Deyo Comorbidity score of 1 (HR 1.1, 95% CI 1.01-1.2; P = 0.02), Charlson-Deyo Comorbidity score of 2 (HR 1.5, 95% CI 1.3-1.7; P < 0.001), stage cT3-4 (HR 1.4, 95% CI 1.3-1.6; P < 0.001), and urothelial histology (HR 1.2, 95% CI 1.1-1.3; P < 0.001) were significant predictors of worse OS (Table 3 ). In the matched CRT cohort (N = 1 683), 26 patients (2%) underwent RC within 2 years following treatment.
Discussion
Our present results show that there may be a short-term survival advantage with CRT for cT2-4, N0, M0 urothelial bladder cancer in the first year after treatment for MIBC, but that beyond 2 years, mortality risk is lower for those undergoing RC. We also found that that 5-year OS is better with RC compared to CRT (38% vs 30%, P < 0.004) in patients matched for age, comorbidities, and disease characteristics. Long-term data from centres of excellence report a 5-and 10-year OS after RC of 58-66% and 43-44%, respectively [4, 12] . Our present 5-year OS for RC (38%) was lower than that reported from experienced centres, probably due to patient selection using propensity matching to CRT patients and inclusion of data from centres with relatively lower volumes and less experience [13] . Whilst CRT is not typically considered standard of care for MIBC, emerging data support bladder preservation [1] . A pooled analysis of long-term CRT data from the Radiation Therapy Oncology Group (RTOG) trials demonstrate 5-and 10-year OS rates of 57% and 36%, respectively [5] . Whilst, the present study does not assess the comparative efficacy of a particular RTOG protocol-derived regimen, it does provide a general basis for comparison of CRT within an established dose range in national clinical practice. Given similar reported survival rates from independent CRT and RC series, it has been hypothesised that both treatments offer similar outcomes. However, direct comparison of independent series risks misleading conclusions. For RC, clinical factors such as patient comorbidity, age; and pathological features, such as tumour stage, histological sub-type, and grade correlate with survival [14, 15] . For patients undergoing CRT, predictors of response and survival include: tumour stage, presence of hydronephrosis, complete TURBT, multifocality, presence of carcinoma in situ, type of chemotherapy, radiation dose, and technique [2, 16] . Therefore, both patient populations are heterogeneous thereby precluding meaningful comparison of survival outcomes using individual, unmatched series.
Given the lack of direct comparative data for CRT and RC, we sought to develop a model to predict and compare survival using propensity score matching to account for heterogeneity and bias based on known predictors of survival. Our present findings are in contrast to those of Gofrit et al. [17] , who found no difference in OS between CRT and RC in a single institution series. However, both groups in that study were significantly different with respect to comorbidity, and there was no adjustment for selection bias in their analysis. Bekelman et al. [18] reported improved survival with RC compared to CRT using propensity score matching in the Surveillance, Epidemiology and End Results (SEER)-Medicare registry. Interestingly, they performed an alternate method, instrumental variable analysis, which accounts for both measured and 'unmeasured' confounders, and subsequently found no survival difference. Gore et al. [19] performed a similar analysis in SEER-Medicare, using instrumental variable analysis, and demonstrated better 5-year adjusted OS for RC vs radiation (42.2% vs 20.7%). The reported HR of death was 1.5 (95% CI 1.3-1.8) for chemotherapy and/or radiation vs RC, and supports our present study results [(19) ]. Kulkarni et al. [20] reported a propensity score matched, single institution series of TMT vs RC and found no difference in DSS and OS. The main limitation of that study is the selection bias due to a small sample size from a select group of patients referred to a multidisciplinary bladder cancer clinic, from a single institution. Recently, a comparative analysis of TMT vs RC using the NCDB was conducted in a slightly different population of patients with MIBC [7] . The TMT cohort (N = 1 257 vs 1 773 CRT cohort in present study) included patients with a higher radiation dose 60-65 Gy and those who underwent RC immediately after ≥39 Gy of palliative radiotherapy. Interestingly, whilst the authors did not find a significant difference in median OS (40 vs 43 months) for TMT vs RC, it is noteworthy that, similar to the present study, there was an initial nonsignificant decreased likelihood of mortality with TMT but that after 2 years there was a transition such that TMT was associated with a time dependent 1.4-fold increased likelihood of death compared to RC [7] .
Whilst the durable (≥2 years) survival benefit favours RC, it is interesting that the initial likelihood of mortality was higher for RC during the first 16 months in the present study. The initial decrease in survival is probably explained by surgical morbidity and mortality. Complication rates after RC range from 30% to 70% and whilst most complications are minor (Clavien-Dindo grade 1-2), up to 24% may be major (Clavien-Dindo grade 3-5) [21] [22] [23] . Long-term studies show that the mortality rate after RC may be as high as 7.9-12.7% in the 90-day postoperative period [14, 24] . Furthermore, several factors contribute to increased risk of early mortality including age, disease stage, nutrition status, comorbidities, and hospital volume [22, 24] . Therefore, the relatively higher morbidity and mortality inherent with RC in the early perioperative period, compared to CRT, can probably explain the trend towards decreased OS within the initial 16 months. Alternatively, cancer recurrence and progression could account for initial decreased survival; however, this is unlikely given that early DSS after RC is relatively high [4] .
Despite propensity score matching, the present study does have limitations. Firstly, propensity scoring does not completely eliminate selection bias, and unmeasured or unknown predictors of survival, such as molecular genetic factors [25] may account for differences in survival, particularly in observational registry studies [26, 27] . Second, whilst we applied stringent criteria to define CRT, we were unable to control for improvements and variability in the quality of radiotherapy over time, type of chemotherapy, or 'completeness' of TURBT. Another limitation is the variability in use of perioperative chemotherapy in patients undergoing RC. Studies show a survival benefit with neoadjuvant chemotherapy [28] ; however, utilisation in the NCDB is low [29] . Finally, we were unable to infer whether mortality was cancer related or non-cancer related because the NCDB does not provide information on disease recurrence or DSS.
Limitations notwithstanding, our present findings suggest that RC may be beneficial in those patients who are suitable surgical candidates with long-life expectancy, compared to CRT. In contrast, patients who are high-risk surgical candidates may be better served by CRT given the decreased OS associated with RC in the first 16 months.
Conclusion
Our present results support existing data that demonstrate that age, comorbidity, tumour stage, grade, and histological subtype are important predictors of OS after RC [30] .
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Furthermore, in a cohort of propensity matched patients undergoing RC and CRT, when controlling for known predictors of outcome, there is a survival advantage with RC at ≥2 years following treatment. However, patient selection for RC is critical, because the associated morbidity and increased relative risk of mortality within the first year after treatment may limit the survival benefit compared to CRT.
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